key: cord-0931925-g790wbzs authors: Girardelli, Serena; Mullins, Edward; Lees, Christoph C. title: COVID-19 and pregnancy: lessons from 2020 date: 2021-09-01 journal: Early Hum Dev DOI: 10.1016/j.earlhumdev.2021.105460 sha: ffdecb71be83b9c298060b340dc0a41ce841427d doc_id: 931925 cord_uid: g790wbzs The outbreak and spread of the coronavirus disease 2019 pandemic has led to an unprecedented wealth of literature on the impact of human coronaviruses on pregnancy. The number of case studies and publications alone are several orders of magnitude larger than those published in all previous human coronavirus outbreaks combined, enabling robust conclusions to be drawn from observations for the first time. However, the importance of learning from previous human coronavirus outbreaks cannot be understated. In this narrative review, we describe what we consider to the major learning points arising from the SARS-CoV-2 pandemic in relation to pregnancy, and where these confound what might have been expected from previous coronavirus outbreaks. became apparent in the first few months of the pandemic, [19] and it is perhaps not surprising therefore that dexamethasone has been found to be an effective treatment for COVID-19 disease. [20] Prednisolone is the preferred choice in pregnant women, due to its limited transplacental transfer, thus avoiding the effects on the fetus of repeated high dose steroids. [21] The question of how much tropism coronaviruses have for cells other than penumocytes is still open; in MERS-CoV cases as opposed to SARS CoV-1, severe renal damage was diagnosed in more than 50% of cases after the incubation period, [22] [23] leading to the suggestion of a new target site in the renal tissue. The presence of ACE2 and TPRSS2 on trophoblast cells was also investigated during the first months of the 2020 pandemic. [24] [25] [26] Pregnant patients are more vulnerable to pulmonary infections as there is a physiological elevation of the diaphragm; the end-expiratory abdominal pressure rises, increasing the negative pressure within the pleural cavities that keeps the alveoli from collapsing. There is a partial closure of the smaller airways, a reduction of functional residual capacity, a decrease of the expiratory reserve volume and therefore, ultimately, an increased susceptibility to pulmonary infections. [27] Patients manifesting more severe coronavirus symptoms are subject to the development of pulmonary damage after pulmonary infection resulting in a clinical picture known as acute respiratory distress syndrome (ARDS). The causal trigger is the pulmonary endothelial cell dysfunction that follows pneumocyte damage. It is still unclear if the peripheral vasodilation that physiologically occurs during pregnancy has any role in ARDS development. [17] In addition to respiratory modifications, the coagulation status of pregnant patients is swayed towards hypercoagulability; patients affected by SARS-CoV-2, are known to be more exposed to thromboembolic complications than the general population and guidelines recommend anticoagulation for all hospitalised SARS-CoV-2 positive patients. [11] Although no reports on thrombotic events in pregnancies complicated by SARS-CoV-1 or MERS-CoV are available, they have been reported in the general population. The first UK Obstetric Surveillance System (UKOSS) report investigated the characteristics of hospitalized women during the first months of the pandemic. [14] Over half were "black or other minority ethnic group", and this was also confirmed in a systematic review of international papers, [29] establishing the greater risk of hospitalization for this population. Of note, we cannot compare this finding with what previously learnt from the other HCoV as these affected mainly patients from Asian and Middle Eastern geographical regions. Other noticeable risk factors to consider when managing pregnancies complicated by COVID-19 are those that lead to a baseline increase in endothelial dysfunction, such as obesity, hypertension and diabetes. Vitamin D deficiency has been thought to play a role in progression in disease progression, although its supplementation in SARS-CoV-2 positive pregnant patients is not based on robust evidence. [14] As expected, given the tropism HCoV have for pneumocytes, a strong association between HCoV infection and pneumonia has been recorded in the literature (up to 88.9% in SARS-CoV-1 and 71.4% in MERS-CoV). [30] Although the correlation initially appeared to be less pronounced for SARS-CoV-2 infections in a UK national population cohort study (24% of hospitalised women with confirmed SARS-CoV- had a fever, 37.2% had a cough and 14% reported fatigue. Similarly, the prevalence of dyspnea was reported being 50% for MERS and up to 90% in SARS-CoV-1, but only in 22.1% of SARS-CoV-2 infected patients, while myalgia was reported in 37.5% of MERS affected pregnant patients and up to 72.7% of SARS patients compared to 9.7% of SARS-CoV-2 patients. [30] Pregnancy induced hypertension (PIH) and pre-eclampsia (PET) are characterised by underlying endothelial cell dysfunction, similar to the effect SARS-CoV-2 mainly has on the pulmonary endothelium. As a result, pregnancies complicated by pre-eclampsia could be expected to be at increased risk for HCoV related complications (and vice versa). [30] In reality, the incidence of PIH and PET in pregnancies complicated by a COVID-19 diagnosis remains unelucidated, as the PANCOVID [32] data showed no excess in PIH and PET compared to historic norms while a prospective international cohort study (INTERCOVID Multinational Cohort Study) found an increased relative risk (1.76, CI 1.27 to 2.43) for PET compared to general pregnant population, [33] as did a UK based national cohort study. [34] Furthermore, we know that COVID-19 related morbidity is higher in pregnant patients with other risk factors for endothelial dysfunction such as raised body mass index (BMI) and pre-existing cardiac disease. [14] Whilst one woman out of 8 with MERS-CoV infection (12.5%, CI 0-53.6) developed preeclampsia, there were no cases with this complication in two SARS-CoV-1 infected patients reported. [30] Interestingly, fetal consequences of placental dysfunction such as intrauterine fetal growth restriction (IUGR) or small for gestational age (SGA) fetuses appear not to be increased in pregnancies complicated by SARS-CoV-2 infections, [32] [33] despite reports of this in the earlier stages of the pandemic. [35] There is Incubation period (days) [ The effect of Asian influenza on the outcome of pregnancy pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview Epidemiology and evolution of Middle East respiratory syndrome coronavirus SARS-CoV-2 and the pandemic of COVID-19 Transmission From People Without COVID-19 Symptoms Assessment and management of asymptomatic COVID-19 infection: A systematic review COVID-19) Infection in Pregnancy Syndrome Coronavirus Infection During Pregnancy: A Report of 5 Cases From Saudi Arabia Coronavirus in pregnancy and delivery: rapid review Pregnancy and COVID-19 Ten scientific reasons in support of airborne transmission of SARS-CoV-2 Novel Middle East respiratory syndrome and renal failure The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study Does the human placenta express the canonical cell entry mediators for SARS-CoV-2? Elife Expression of SARS-CoV-2 receptor ACE2 and the protease TMPRSS2 suggests susceptibility of the human embryo in the first trimester Respiratory physiology of pregnancy: Physiology masterclass. Breathe (Sheff) Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes The effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-fetal transmission: a systematic review and meta-analysis Impact of COVID-19 on maternal and neonatal outcomes: a systematic review and meta-analysis Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections ACE2 Is Expressed in Immune Cells That Infiltrate the Placenta in Infection /ACE2 on the female reproductive system SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis ISTH interim guidance on recognition and management of coagulopathy in COVID-19 COVID-19 and acute coagulopathy in pregnancy Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis Association of Maternal Perinatal SARS-CoV-2 Infection With Neonatal Outcomes During the COVID-19 ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals Maternity services in the UK during the coronavirus disease 2019 pandemic: a national survey of modifications to standard care ICNARC Covid-19 reports Change in the Incidence of Stillbirth and Preterm Delivery During the COVID-19 Pandemic Coronavirus vaccine development: from SARS and MERS to COVID-19 Consider pregnancy in COVID-19 therapeutic drug and vaccine trials Importance of Inclusion of Pregnant and COVID-19 Therapeutic Trials vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21. Res Sq Use of the AstraZeneca COVID-19 (AZD1222) vaccine: updated JCVI statement Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future? Attitudes towards human papillomavirus vaccination among African parents in a city in the north of England: a qualitative study Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study The ability of the neonatal immune response to handle SARS-CoV-2 infection